Sema4 Holdings Corp. - Class A Common Stock (NQ:SMFR)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sema4 Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 Next >

Sema4 Holdings Corp. (NASDAQ: SMFR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing ↗

February 08, 2023

San Diego, CA -- (SBWIRE) -- 02/08/2023 -- An investigation was announced for current long-term investors in shares of Sema4 Holdings Corp. (NASDAQ: SMFR) concerning potential breaches of fiduciary...

Via SBWire

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.

Via Benzinga

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

January 09, 2023

From GeneDx Holdings Corp.

Via GlobeNewswire

Sema4 Holdings's Return on Invested Capital Overview ↗

December 26, 2022

Via Benzinga

What To Know About Goldman Sachs's Downgrade of Sema4 Holdings ↗

December 07, 2022

Via Benzinga

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 30, 2022

Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation

From Sema4

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

December 29, 2022

On Thursday, 116 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

December 12, 2022

Monday saw 196 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 09, 2022

On Friday, 127 companies set new 52-week lows.

Via Benzinga

ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday ↗

December 07, 2022

Barclays raised ConocoPhillips (NYSE: COP) price target from $135 to $151. Barclays analyst Jeanine Wai maintained an Overweight rating on the stock. ConocoPhillips shares fell 3.2% to close at $115.61...

Via Benzinga

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

December 05, 2022

Data underscores the value of mitochondrial DNA testing and the opportunity to improve health outcomes for critically ill newborns with early medical intervention

From Sema4

Via GlobeNewswire

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

November 14, 2022

From Sema4

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

December 02, 2022

On Friday, 72 companies hit new 52-week lows.

Via Benzinga

NASDAQ:SMFR Investor Alert: Deadline on November 7, 2022 in Lawsuit Against Sema4 Holdings Corp. ↗

November 09, 2022

San Diego, CA -- (SBWIRE) -- 11/09/2022 -- The Shareholders Foundation announced that a deadline is coming up on November 7, 2022 in the lawsuit filed for certain investors of Sema4 Holdings Corp....

Via SBWire

Deadline Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders of Last Few Hours to Actively Participate

November 07, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

November 30, 2022

During Wednesday's session, 107 stocks hit new 52-week lows.

Via Benzinga

Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday ↗

November 17, 2022

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

November 16, 2022

On Wednesday, 70 companies set new 52-week lows.

Via Benzinga

SMFR FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW

November 07, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Earnings Scheduled For November 14, 2022 ↗

November 14, 2022

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm

November 06, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

SMFR FINAL DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW

November 06, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

SEMA4 HOLDINGS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Sema4 Holdings Corp. - SMFR

November 04, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

November 04, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm

October 31, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

October 31, 2022

Guideline adoption can help end the diagnostic odyssey experienced by many families

From Sema4

Via GlobeNewswire

ROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp. Investors With Losses Over $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW

October 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

October 27, 2022

From Sema4

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm

October 26, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

October 26, 2022

Exome and genome tests report 30% fewer inconclusive results and a higher diagnostic yield compared to multi-gene panel tests; research to be presented at American Society of Human Genetics Annual...

From Sema4

Via GlobeNewswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.